Leadership & Pay ·
NewAmsterdam Pharma Co. disclosed that Chief Operating Officer Douglas Kling resigned effective August 14, 2026, to…
NAMSNewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Co. disclosed that Chief Operating Officer Douglas Kling resigned effective August 14, 2026, to become CEO of another clinical-stage biotech company. Unvested stock options and restricted stock units were canceled, except for those eligible to vest through May 14, 2027 contingent on his advisory services. Mr. Kling entered an Advisor Agreement providing transition support for the PREVAIL clinical trial of obicetrapib in exchange for a $50,000 monthly fee plus expenses until May 14, 2027. The company operates as a clinical-stage biopharmaceutical firm focused on developing treatments for metabolic and cardiovascular diseases.